Metabonomic diagnosis of bladder cancer: what are the advantages and considerations?

What is it about?

Bladder cancer (BC) is the fifth most common cancer and is one of the leading causes of death worldwide. The 5-year survival rate for BC is approximately 94% if detected early; thus timely diagnosis and intervention of BC increase patient's survival rate dramatically. However, BC has a high recurrence rate and patients are subjected to life-long surveillance. As a result, the lifetime economic burden per BC patient is higher than other cancer types. Currently, the standard diagnoses of BC are cystoscopy and urinary cytology. While cystoscopy is clinically reliable, it is expensive, invasive and associated with a definite risk of morbidity. On the other hand, noninvasive urinary cytology demonstrates poor sensitivity in detecting low-grade BC (4–31%). In recent years, several proteinaceous urine-based bladder tumor markers (UBBTMs) have been evaluated for the diagnosis of BC, such as bladder tumor antigen (BTA), NMP22, FDP and ImmunoCyt. However, the specificity and sensitivity of current molecular biomarkers are not adequate to replace cystoscopy. Therefore, there is an impetus to develop sensitive and specific noninvasive biomarkers for the diagnosis and surveillance of BC. Dysregulated molecular pathways, associated with tumor genes, secrete specific modulated levels of metabolites into biological fluids that may be detectable prior to clinical symptoms, rendering them potential early biomarkers for cancer diagnosis. Metabonomics measures the dynamic multiparametric responses of systems biological metabolome to genetic modifications or pathophysiological stimuli such as cancers. It allows scientists to survey global dysregulated metabolic pathways and gain holistic insights into cancer etiology and progression. Significant progress has been made using modern metabonomics techniques to characterize BC patients, identify marker metabolites and generate new knowledge in disease biology and potential therapeutic targets.

Featured Image

Why is it important?

The application of metabonomics in the diagnosis of BC is particularly intriguing due to the possibility of using urine for detecting malignancy and determining prognosis. As urine is bathed in close anatomical proximity to the bladder carcinoma, it is expectedly a suitable diagnostic fluid. Advantages of urinary metabonomics profiling of BC include noninvasive sample collection, relative ease of urine analysis, low-cost, circumvention of subjective pathological assessment and urinary metabolic phenotype (metabotype) that is sensitive to environmental, gut microbiota and host genetic factors. Most current BC metabonomics studies showed that BC patients could be distinctly differentiated from healthy controls with high sensitivity (>90%) and specificity (>90%). A number of potential marker metabolites of BC are derived from metabolic pathways associated with glycolysis, glutathione, tryptophan, purine, pyrimidine, carnitine, citrate, taurine and hippuric acid. Such dysregulated marker metabolites are useful in deciphering the BC biology and have the potential to be translated to clinical applications upon further evaluation and validation. In addition to accurate diagnosis, classification of bladder tumors is important for prognosis of BC. However, reproducibility and consistency in defining superficial bladder tumors is a chronic challenge for pathologists. Notably, Cao et al. demonstrated that distinct metabotypes were associated with low-grade versus high-grade BC as well as pre- versus post-transurethral resected cohorts [15]. Additionally, two BC metabonomics studies exhibited potential in the staging and grading of bladder tumors. Based on the direct correlation of metabolic features with pathological status, this technique will provide a mechanistic handle for probing the progression of BC. Monitoring treatment and recurrence is critical for BC patients. Recently, Jin et al. demonstrated in a large cohort study (138 BC and 121 healthy controls) that BC metabotype correlates positively with cancer-specific survival time, which in turn underscores the possibility of predicting postdiagnosis survival time of BC patients via metabonomics. As both bladder and kidney are in direct contact with urine, it is possible that marker metabolites associated with BC and kidney cancer are excreted into urine. Intriguingly, it has been reported that metabonomics can discriminate BC and kidney cancer successfully, showing 100% sensitivity and specificity.

Perspectives